Twist Bioscience (NASDAQ:TWST) Insider Dennis Cho Sells 412 Shares of Stock

Twist Bioscience Corporation (NASDAQ:TWST) insider Dennis Cho sold 412 shares of the stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $122.62, for a total value of $50,519.44. Following the sale, the insider owned 73,651 shares of the company’s stock, valued at $9,031,085.62. This trade represents a 0.56% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Dennis Cho also recently made the following trade(s):

• On Wednesday, June 24th, Dennis Cho sold 14,205 shares of Twist Bioscience stock. The stock was sold at an average price of $89.75, for a total transaction of $1,274,898.75.
• On Monday, June 22nd, Dennis Cho sold 346 shares of Twist Bioscience stock. The stock was sold at an average price of $87.32, for a total value of $30,212.72.

Twist Bioscience Price Performance

NASDAQ TWST opened at $126.85 on Friday. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.67 and a quick ratio of 2.38. The firm has a market capitalization of $7.95 billion, a price-to-earnings ratio of -57.14 and a beta of 2.22. The company has a 50 day simple moving average of $112.95 and a 200-day simple moving average of $78.99. Twist Bioscience Corporation has a 52-week low of $23.30 and a 52-week high of $155.44.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Monday, August 3rd. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%.The company had revenue of $118.38 million during the quarter, compared to analysts’ expectations of $114.55 million. During the same quarter in the previous year, the company earned $0.33 EPS. The firm’s quarterly revenue was up 23.2% compared to the same quarter last year. Equities research analysts predict that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Key Headlines Impacting Twist Bioscience

Here are the key news stories impacting Twist Bioscience this week:

• Positive Sentiment: UBS initiated coverage with a Neutral rating and a $144 price target, implying additional upside from the referenced price. While the rating is not bullish, the target provides some support for the stock’s elevated valuation. UBS initiates coverage of Twist Bioscience with neutral rating
• Positive Sentiment: Twist Bioscience is scheduled to present at the Baird 2026 Global Healthcare Conference. The event could give management an opportunity to discuss demand, growth prospects and its biotechnology platform, potentially increasing investor visibility. Twist Bioscience to Present at Baird 2026 Global Healthcare Conference
• Neutral Sentiment: Insider Dennis Cho sold 412 shares for approximately $50,519, reducing his holdings by only 0.56%. Because the transaction was made to cover tax withholding related to vested equity awards, it appears less concerning than a discretionary sale.
• Neutral Sentiment: The reported short-interest data shows zero shares short and a zero-day short ratio, with the stated increase listed as “NaN.” This appears to be a data-quality issue rather than evidence of a meaningful change in bearish positioning.
• Neutral Sentiment: A broader article on accelerating AI and robotics adoption could support long-term interest in biotechnology automation and laboratory tools, but it does not identify a specific new catalyst for Twist Bioscience. AI and Robotics in 2026
• Negative Sentiment: BWS Financial initiated coverage with a Sell rating and a $45 price target, implying substantial downside from the referenced price. This sharply bearish target highlights valuation concerns and is the strongest negative catalyst in the latest coverage.

Analyst Upgrades and Downgrades

Several brokerages recently commented on TWST. UBS Group started coverage on Twist Bioscience in a research note on Wednesday. They issued a “neutral” rating and a $144.00 price target for the company. Guggenheim reaffirmed a “buy” rating on shares of Twist Bioscience in a research report on Monday, August 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Twist Bioscience in a research note on Wednesday, June 24th. Evercore downgraded shares of Twist Bioscience from an “outperform” rating to an “in-line” rating and set a $102.00 target price for the company. in a research report on Monday, July 6th. Finally, Leerink Partners set a $110.00 price target on shares of Twist Bioscience in a report on Thursday, July 16th. Eight equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Twist Bioscience currently has a consensus rating of “Moderate Buy” and a consensus price target of $98.45.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Quarry LP bought a new stake in shares of Twist Bioscience in the third quarter valued at approximately $28,000. Western Wealth Management LLC acquired a new position in Twist Bioscience during the 1st quarter valued at $31,000. Strs Ohio acquired a new position in Twist Bioscience during the 1st quarter valued at $33,000. Strategic Advocates LLC boosted its holdings in Twist Bioscience by 562.7% in the 4th quarter. Strategic Advocates LLC now owns 1,067 shares of the company’s stock valued at $34,000 after purchasing an additional 906 shares during the period. Finally, SBI Securities Co. Ltd. grew its position in Twist Bioscience by 68.9% in the 4th quarter. SBI Securities Co. Ltd. now owns 1,400 shares of the company’s stock worth $44,000 after purchasing an additional 571 shares during the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA using a proprietary silicon-based platform. The company serves researchers and organizations in biotechnology, pharmaceutical development, agriculture, industrial chemicals and academic research.

Its products include synthetic genes, gene fragments, oligonucleotides and DNA libraries used in research, drug discovery, diagnostics development and other applications. Twist also provides next-generation sequencing tools and products, including target-enrichment and sample-preparation solutions, as well as synthetic biology services that support the design and testing of biological systems.

Twist was founded in 2013 and is headquartered in South San Francisco, California.